<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436200</url>
  </required_header>
  <id_info>
    <org_study_id>14HH1909</org_study_id>
    <nct_id>NCT02436200</nct_id>
  </id_info>
  <brief_title>Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication</brief_title>
  <acronym>IC</acronym>
  <official_title>Neuromuscular Electrical Stimulation in Patients With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the benefit of a neuromuscular electrical stimulation device in
      patients suffering from symptoms and effects of lower limb intermittent claudication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The circulation of blood around the body is dependent on effective pumping of the heart.
      Patients with claudication experience pain or discomfort in their legs usually during
      activity such as walking, which goes away at rest. Claudication is a symptom of peripheral
      arterial disease (PAD). If left untreated, patients can develop arterial insufficiency which
      can lead to various complications such as swelling, painful legs, reduced healing of injuries
      and the loss of limbs in extreme conditions.

      PAD can be defined as a narrowing of the arteries reducing blood flow. It is most commonly
      due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its
      incidence is estimated at 7-14% in the general population, increasing with age to about 20%
      in the over-seventies. It is associated with effects on mobility, skin condition and quality
      of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at
      rest (particularly at night), gangrene, and limb loss. Management of PAD is based on
      encouraging exercise, and modification of risk factors such as smoking, high blood pressure,
      high cholesterol and diabetes.

      In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be
      treated by procedures such as balloon angioplasty, stenting or surgical bypass, but these
      procedures have risks. There also remains a percentage of patients who are not suitable for
      revascularisation, and have few options besides amputation available to them.

      Some trials have shown that increasing the blood flow in the legs over time using medical
      devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal
      medical and surgical therapy, can increase claudication distance, absolute walking distance,
      decrease rest pain, and reduce amputation rates. In our unit it has become apparent that
      there are an increasing number of medical devices available for circulatory support, either
      for use as an inpatient, out-patient, or a member of the general public. The supporting
      evidence for these is variable in scientific and clinical content or relevance, and requires
      clinical trials to evaluate further.

      The device being used in this study, activates the pumping action of the leg muscles by
      providing neuromuscular electrical stimulation (NMES) to cause foot muscle contraction and
      relaxation. This squeezes blood back towards the heart, improving circulation.

      The study will evaluate whether NMES using this device has the same beneficial effects in
      patients with intermittent claudication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Walking Distance Measured by Treadmill</measure>
    <time_frame>Change in baseline treadmill walking distance at 6 weeks</time_frame>
    <description>For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Walking Distance Measured by Treadmill</measure>
    <time_frame>Change in baseline treadmill walking distance at 6 weeks</time_frame>
    <description>For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography</measure>
    <time_frame>Change in baseline femoral haemodynamics at 6 weeks</time_frame>
    <description>Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laser Doppler Flow Measured by Optical Laser</measure>
    <time_frame>Change in baseline flowmetry at 6 weeks</time_frame>
    <description>Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Scores by Questionnaire</measure>
    <time_frame>Change in baseline questionnaire scores at 6 weeks</time_frame>
    <description>Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scores Measured by Questionnaire</measure>
    <time_frame>Change in baseline quality of life at 6 weeks</time_frame>
    <description>Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Metabolic Profile</measure>
    <time_frame>Change of profile at baseline and at 6 weeks</time_frame>
    <description>A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Metabolic Profile</measure>
    <time_frame>Change of profile at baseline and 6 weeks</time_frame>
    <description>A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Intermittent Claudication</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving neuromuscular electrical stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuromuscular Electrical Stimulation</intervention_name>
    <description>Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All ethnic groups, male or female above the age of 18 years.

          -  Diagnosis of mild intermittent claudication

          -  Be of non-childbearing potential; OR using adequate contraception and have a negative
             urine pregnancy test result within 24 hours if appropriate before using the study
             device.

          -  Blood pressure currently under moderate control (&lt; 160/100mmHg)

          -  No current foot ulceration

        Exclusion Criteria:

          -  Patients meeting any of the following criteria are to be excluded:

               -  Has an unstable condition (eg, psychiatric disorder, a recent history of
                  substance abuse) or otherwise thought to be unreliable or incapable of complying
                  with the study protocol.

               -  Has diabetes

               -  Ankle Brachial Pressure Index &gt; 0.9

               -  Has any metal implants

               -  Pregnant

               -  Has a cardiac pacemaker or defibrillator device

               -  Has recent lower limb injury or lower back pain

               -  Has current foot ulceration or other skin ulcers

               -  Has foot deformities

               -  Has any disorder that, in the opinion of the Investigator, might interfere with
                  the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alun H Davies, BA BMChB MA</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College London - Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>Hammersmith</state>
        <zip>W6 8FS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent Claudication</keyword>
  <keyword>IC</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Peripheral Arterial Occlusive Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Patients receiving neuromuscular electrical stimulation.
Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Significant outlier</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Patients receiving neuromuscular electrical stimulation.
Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index - BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle Brachial Pressure Index - ABPI (Right)</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.71" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle Brachial Pressure Index - ABPI (Left)</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.69" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Claudication Distance - ICD (m)</title>
          <units>m</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" lower_limit="29" upper_limit="64.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum Claudication Distance - MCD (m)</title>
          <units>m</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.3" lower_limit="57.8" upper_limit="138.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Initial Walking Distance Measured by Treadmill</title>
        <description>For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.</description>
        <time_frame>Change in baseline treadmill walking distance at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receiving neuromuscular electrical stimulation.
Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Walking Distance Measured by Treadmill</title>
          <description>For the initial claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The initial claudication distance (ICD) is the distance walked until the onset of pain.</description>
          <units>metres</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="48" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Walking Distance Measured by Treadmill</title>
        <description>For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.</description>
        <time_frame>Change in baseline treadmill walking distance at 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Patients receiving neuromuscular electrical stimulation.
Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Walking Distance Measured by Treadmill</title>
          <description>For the absolute claudication distance measurement, a fixed load treadmill test will be carried out at 3.5 km/h with a 10% gradient. The absolute claudication distance (ACD) is the distance walked before the participant is forced to stop due to typical pain.</description>
          <units>m</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="85.9" upper_limit="281.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Haemodynamics Measured by Femoral Artery Duplex Ultrasonography</title>
        <description>Ultrasound assessment of blood flow dynamics in the femoral artery will be obtained at rest, and if randomised to the intervention group, whilst using the device.</description>
        <time_frame>Change in baseline femoral haemodynamics at 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laser Doppler Flow Measured by Optical Laser</title>
        <description>Optical laser flowmetry probes will be used to assess the superficial skin circulation and temperature.</description>
        <time_frame>Change in baseline flowmetry at 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic Scores by Questionnaire</title>
        <description>Validated questionnaires including the Edinburgh Claudication Questionnaire and Intermittent Claudication Questionnaire will be obtained at baseline and week 6.</description>
        <time_frame>Change in baseline questionnaire scores at 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Scores Measured by Questionnaire</title>
        <description>Validated questionnaires including the Euro-Quol 5D and Short Form 36 will be measured at baseline and 6 weeks.</description>
        <time_frame>Change in baseline quality of life at 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Metabolic Profile</title>
        <description>A urine sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.</description>
        <time_frame>Change of profile at baseline and at 6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Metabolic Profile</title>
        <description>A serum sample will be collected at baseline and at 6 weeks. Mass spectroscopy and nuclear magnetic resonance spectroscopy analysis will be carried out.</description>
        <time_frame>Change of profile at baseline and 6 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks - duration of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Patients receiving neuromuscular electrical stimulation.
Neuromuscular Electrical Stimulation: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small scale pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Alun Davies, Professor of Vascular Surgery</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 3311 7309</phone>
      <email>a.h.davies@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

